{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:45:06Z","timestamp":1760147106755,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070932","31770184","32170944"],"award-info":[{"award-number":["32070932","31770184","32170944"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Genital herpes (GH) has become one of the most common sexually transmitted diseases worldwide, and it is spreading rapidly in developing countries. Approximately 90% of GH cases are caused by HSV-2. Therapeutic HSV-2 vaccines are intended for people already infected with HSV-2 with the goal of reducing clinical recurrences and recurrent virus shedding. In our previous work, we evaluated recombinant adenovirus-based vaccines, including rAd-gD2\u0394UL25, rAd-\u0394UL25, and rAd-gD2, for their potency as prophylactic vaccines. In this study, we evaluated these three vaccines as therapeutic vaccines against acute and recurrent diseases in intravaginal challenged guinea pigs. Compared with the control groups, the recombinant vaccine rAd-gD2\u0394UL25 induced a higher titer of the binding antibody, and rAd-gD2 + rAd-\u0394UL25 induced a higher titer of the neutralizing antibody. Both rAd-gD2\u0394UL25 and rAd-gD2 + rAd-\u0394UL25 vaccines significantly enhanced the survival rate by 50% compared to rAd-gD2 and reduced viral replication in the genital tract and recurrent genital skin disease. Our findings provide a new perspective for HSV-2 therapeutic vaccine research and provide a new technique to curtail the increasing spread of HSV-2.<\/jats:p>","DOI":"10.3390\/v15010219","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T02:05:52Z","timestamp":1673575552000},"page":"219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["An Adenovirus-Based Recombinant Herpes Simplex Virus 2 (HSV-2) Therapeutic Vaccine Is Highly Protective against Acute and Recurrent HSV-2 Disease in a Guinea Pig Model"],"prefix":"10.3390","volume":"15","author":[{"given":"Mingming","family":"Wan","sequence":"first","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Ding","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Chen","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-7423","authenticated-orcid":false,"given":"Weiheng","family":"Su","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"},{"name":"Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-1868","authenticated-orcid":false,"given":"Linjun","family":"Cai","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"},{"name":"Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Hou","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"},{"name":"Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"},{"name":"Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"},{"name":"Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlai","family":"Jiang","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"},{"name":"Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-2215","authenticated-orcid":false,"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"},{"name":"Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"385697","DOI":"10.1155\/2012\/385697","article-title":"Herpes Simplex Virus Infection in Pregnancy","volume":"2012","author":"Straface","year":"2012","journal-title":"Infect. Dis. Obstet. Gynecol."},{"key":"ref_2","unstructured":"WHO (2023, January 12). Available online: https:\/\/www.who.int\/news\/item\/01-05-2020-billions-worldwide-living-with-herpes."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.vaccine.2008.11.074","article-title":"Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa","volume":"27","author":"Freeman","year":"2009","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(94)92581-X","article-title":"Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes","volume":"343","author":"Straus","year":"1994","journal-title":"Lancet"},{"key":"ref_5","first-page":"235","article-title":"A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections","volume":"70","author":"Casanova","year":"2002","journal-title":"Cutis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0264-410X(88)90215-0","article-title":"Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences","volume":"6","author":"Benda","year":"1988","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa1003509","article-title":"Oral acyclovir suppression and neurodevelopment after neonatal herpes","volume":"365","author":"Kimberlin","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.med.59.061606.095540","article-title":"Herpes simplex: Insights on pathogenesis and possible vaccines","volume":"59","author":"Koelle","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10894","DOI":"10.1128\/JVI.76.21.10894-10904.2002","article-title":"Structure-Based Analysis of the Herpes Simplex Virus Glycoprotein D Binding Site Present on Herpesvirus Entry Mediator HveA (HVEM)","volume":"76","author":"Connolly","year":"2002","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.mib.2006.06.013","article-title":"Herpesvirus assembly: A tale of two membranes","volume":"9","author":"Mettenleiter","year":"2006","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/viro.1996.0061","article-title":"Characterization of an essential HSV-1 protein encoded by the UL25 gene reported to be involved in virus penetration and capsid assembly","volume":"216","author":"Ali","year":"1996","journal-title":"Virology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1128\/JVI.02659-05","article-title":"Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes","volume":"80","author":"Hosken","year":"2006","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/JVI.78.6.2666-2673.2004","article-title":"Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors","volume":"78","author":"Sumida","year":"2004","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/1348-0421.12482","article-title":"Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice","volume":"61","author":"Liu","year":"2017","journal-title":"Microbiol. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1128\/JVI.02521-10","article-title":"Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease","volume":"85","author":"Morello","year":"2011","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1016\/j.vaccine.2019.08.077","article-title":"Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes","volume":"37","author":"Dib","year":"2019","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.vaccine.2015.10.137","article-title":"A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs","volume":"34","author":"Odegard","year":"2016","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.02745-12","article-title":"An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs","volume":"87","author":"Skoberne","year":"2013","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vaccine.2018.11.042","article-title":"The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/vim.2017.0033","article-title":"Optimized DNA Vaccine Enhanced by Adjuvant IL28B Induces Protective Immune Responses Against Herpes Simplex Virus Type 2 in Mice","volume":"30","author":"Zhou","year":"2017","journal-title":"Viral Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2471\/BLT.07.046128","article-title":"An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection","volume":"86","author":"Looker","year":"2008","journal-title":"Bull. World Health Organ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/591914","article-title":"Asymptomatic Shedding of Herpes Simplex Virus 1 and 2: Implications for Prevention of Transmission","volume":"198","author":"Mertz","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM199911043411904","article-title":"A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group","volume":"341","author":"Langenberg","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.vaccine.2013.01.002","article-title":"Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine","volume":"31","author":"Tavares","year":"2013","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/infdis\/jiac284","article-title":"Herpes Simplex Virus Glycoprotein D Antibodies Fail to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines","volume":"226","author":"Mahant","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_28","first-page":"247","article-title":"An adenovirus-herpes simplex virus glycoprotein B recombinant (Ad-HSV.gB) protects mice against a vaccinia HSV.gB and HSV challenge","volume":"42","author":"Endresz","year":"1995","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S912","DOI":"10.1093\/clind\/13.Supplement_11.S912","article-title":"Adenovirus vectors as potential vaccines against herpes simplex virus","volume":"13","author":"Johnson","year":"1991","journal-title":"Rev. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0042-6822(89)90064-0","article-title":"Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B","volume":"169","author":"McDermott","year":"1989","journal-title":"Virology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/infdis\/168.3.622","article-title":"Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B","volume":"168","author":"Gallichan","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: Deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.4049\/jimmunol.1201121","article-title":"Targeting the genital tract mucosa with a lipopeptide\/recombinant adenovirus prime\/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: Importance of MyD88","volume":"189","author":"Zhang","year":"2012","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1128\/JVI.01089-15","article-title":"A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens","volume":"89","author":"Awasthi","year":"2015","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1006\/viro.1999.9739","article-title":"The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice","volume":"258","author":"Parr","year":"1999","journal-title":"Virology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/jvi.69.8.4898-4905.1995","article-title":"Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1","volume":"69","author":"Cantin","year":"1995","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0167-5699(93)90277-R","article-title":"A case for cytokines as effector molecules in the resolution of virus infection","volume":"14","author":"Ramsay","year":"1993","journal-title":"Immunol. Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.1128\/JVI.74.19.9144-9151.2000","article-title":"Putative Immunodominant Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Cannot Be Predicted by Major Histocompatibility Complex Class I Haplotype","volume":"74","author":"Betts","year":"2000","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e02309-18","DOI":"10.1128\/JVI.02309-18","article-title":"Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4 and CD8 T Cells Associated with Protection against Recurrent Genital Herpes","volume":"93","author":"Srivastava","year":"2019","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104821","DOI":"10.1016\/j.antiviral.2020.104821","article-title":"Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review","volume":"180","author":"Bernstein","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.vaccine.2017.03.065","article-title":"A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus","volume":"35","author":"Wu","year":"2017","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0264-410X(01)00486-8","article-title":"Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation","volume":"20","author":"Jacquet","year":"2002","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.4049\/jimmunol.0803115","article-title":"Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat\/Env compared with multigenic vaccines","volume":"182","author":"Florese","year":"2009","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vaccine.2011.10.040","article-title":"Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques","volume":"30","author":"Bialuk","year":"2012","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e06054","DOI":"10.7554\/eLife.06054","article-title":"Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease","volume":"4","author":"Petro","year":"2015","journal-title":"eLife"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1080\/22221751.2022.2097479","article-title":"Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice","volume":"11","author":"Li","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40588-015-0020-4","article-title":"Herpes Simplex Vaccines: Prospects of Live-Attenuated HSV Vaccines to Combat Genital and Ocular Infections","volume":"2","author":"Stanfield","year":"2015","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1586\/14760584.2014.910121","article-title":"Antigenic breadth: A missing ingredient in HSV-2 subunit vaccines?","volume":"13","author":"Halford","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","article-title":"A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques","volume":"27","author":"Zhang","year":"2021","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10875-010-9441-2","article-title":"Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes","volume":"30","author":"Laing","year":"2010","journal-title":"J. Clin. Immunol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/1\/219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:04:59Z","timestamp":1760119499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/1\/219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["v15010219"],"URL":"https:\/\/doi.org\/10.3390\/v15010219","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}